Frost & Sullivan Independent Equity Research

Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre- IND (505(b)(2) submission; Target price remains unchanged.


Company: D.N.A.-Entera        

Sector: Healthcare

Report type: Q1-2018 Update

Published on: 10 June, 2018

DNA research articles: